Drugs in Dev. Neurology
Phase II
France 
Details : SAR441344 (frexalimab) is a novel monoclonal antibody that is thought to block the costimulatory CD40/CD40L and investigational product relapsing multiple sclerosis.
Product Name : SAR441344
Product Type : Antibody
Upfront Cash : Inapplicable
May 31, 2023
Lead Product(s) : Tolebrutinib
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tolebrutinib is an investigational brain-penetrant Bruton’s tyrosine kinase inhibitor that achieves CSF concentrations needed for targeting B lymphocytes and microglial cells, modulating neuroinflammation.
Product Name : SAR442168
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2021
Lead Product(s) : Tolebrutinib
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolebrutinib
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sanofi brain-penetrant BTK inhibitor meets primary endpoint
Details : Sanofi’s BTK inhibitor will be first disease-modifying therapy to address sources of multiple sclerosis damage in the brain.
Product Name : SAR442168
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 02, 2020
Lead Product(s) : Tolebrutinib
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolebrutinib
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Study’s primary endpoint was met, demonstrating that the BTK inhibitor significantly reduced disease activity associated with multiple sclerosis (MS) as measured by magnetic resonance imaging.
Product Name : SAR442168
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 17, 2020
Lead Product(s) : Tolebrutinib
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amitriptyline Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AlgoTx Reports Positive Phase 2 ATX01 Data in CIPN Treatment
Details : ATX01 (amitriptyline hydrochloride) is being evaluated in the mid-stage clinical trial studies for patients suffering from ChemoTherapy-induced peripheral neuropathy.
Product Name : ATX01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 18, 2025
Lead Product(s) : Amitriptyline Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amitriptyline Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AlgoTx "Last Patient Visit" in Ph II of ATX01 for Chemotherapy-Induced Neuropathy
Details : ATX01 (amitriptyline hydrochloride) is being evaluated in the mid-stage clinical trial studies for patients suffering from ChemoTherapy-induced peripheral neuropathy.
Product Name : ATX01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 23, 2024
Lead Product(s) : Amitriptyline Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ezeprogind
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alzprotect Reports Supportive Results from Phase 2a Study for Progressive PSP
Details : AZP2006 (ezeprogind) is being evalauted in the mid-stage clinical trial studies for the treatment of Progressive Supranuclear Palsy.
Product Name : AZP2006
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 18, 2024
Lead Product(s) : Ezeprogind
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ezeprogind
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Positive Feedback from EMA and FDA on Alzprotect's Phase 2b/3 PSP Development
Details : AZP2006 (ezeprogind) is a small molecule that increases neurotrophic factor Progranulin (PGRN) levels, promoting neuron survival and neurite outgrowth for treating Progressive Supranuclear Palsy.
Product Name : AZP2006
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 13, 2024
Lead Product(s) : Ezeprogind
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mesdopetam
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : IRLAB
Deal Size : Undisclosed
Deal Type : Licensing Agreement
IRLAB Secures Full Ownership of the Mesdopetam Project and Continues Product Development
Details : Under the agreement, IRLAB secured full ownership rights for the now Phase III-ready IRL790 (mesdopetam), a dopamine D3 receptor antagonist, in development as a treatment of Parkinson's disease levodopa-induced dyskinesias.
Product Name : IRL790
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 21, 2023
Lead Product(s) : Mesdopetam
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : IRLAB
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Amitriptyline Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Relyens Innovation Santé
Deal Size : $21.2 million
Deal Type : Series B Financing
AlgoTx Raises €20M to Conduct ATX01’s Phase 2 Program in Peripheral Neuropathic Pain
Details : The net proceedings will be used to demonstrate the clinical efficacy of ATX01 (amitriptyline hydrochloride) in Phase 2 in chemotherapy-induced peripheral neuropathy and erythromelalgia.
Product Name : ATX01
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 14, 2023
Lead Product(s) : Amitriptyline Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Relyens Innovation Santé
Deal Size : $21.2 million
Deal Type : Series B Financing
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
